An overview of evidence- and value-based economic evaluation for health care in chronic disease

- Luan, Luan

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

- Bernhard, Jürg, Luo, Weixiu, Pavesi, Lorenzo, Parmar, Vani, Regan, Meredith M., Pagani, Olivia, Fleming, Gini F., Francis, Prudence A., Price, Karen N., Coates, Alan S., Gelber, Richard D., Goldhirsch, Aron, Ribi, Karin, Walley, Barbara A., Colleoni, Marco, Burstein, Harold J., Tondini, Carlo, Pinotti, Graziella, Spazzapan, Simon, Ruhstaller, Thomas, Puglisi, Fabio

Patient-reported outcomes with neoadjuvant vs adjuvant systemic therapy for operable breast cancer

- Zdenkowski, Nicholas, Butow, Phyllis, Spillane, Andrew, Douglas, Charles, Snook, Kylie, Jones, Mark, Oldmeadow, Christopher, Fewster, Sheryl, Beckmore, Corinna, Boyle, Frances M.

Review article: endpoints used in functional dyspepsia drug therapy trials

- Ang, D., Talley, N. J., Simren, M., Janssen, P., Boeckxstaens, G., Tack, J.

When do patient reported quality of life indicators become prognostic in breast cancer?

- Lee, Chee Khoon, Hudson, Malcolm, Simes, John, Ribi, Karin, Bernhard, Jurg, Coates, Alan